Production (Stage)
Adaptimmune Therapeutics plc
ADAP
$0.2801
$0.00572.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 126.10% | -92.12% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 126.10% | -92.12% | |||
| Cost of Revenue | -24.09% | 14.19% | |||
| Gross Profit | 37.55% | -644.93% | |||
| SG&A Expenses | -24.31% | 34.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.18% | 21.87% | |||
| Operating Income | 31.69% | -339.47% | |||
| Income Before Tax | 35.18% | -332.04% | |||
| Income Tax Expenses | -66.04% | 103.73% | |||
| Earnings from Continuing Operations | 35.88% | -321.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 35.88% | -321.27% | |||
| EBIT | 31.69% | -339.47% | |||
| EBITDA | 32.55% | -419.97% | |||
| EPS Basic | 36.17% | -320.90% | |||
| Normalized Basic EPS | 28.88% | -278.29% | |||
| EPS Diluted | 40.10% | -348.48% | |||
| Normalized Diluted EPS | 28.88% | -278.29% | |||
| Average Basic Shares Outstanding | 0.43% | 0.06% | |||
| Average Diluted Shares Outstanding | 0.43% | 0.06% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||